CD8A and glioma: An intriguing report that utilizes the syngeneic GL261 glioma line demonstrates that anti-VEGF therapy in combination with a picornavirus vaccine (that expresses epitope OVA257–264 to enhance antigen specific CD8+ T-cell) resulted in a synergistic treatment response with prolonged overall survival and delayed disease progression compared to the additive individual effects of these therapies (158).